R W King

Summary

Affiliation: DuPont Pharmaceuticals Company
Country: USA

Publications

  1. ncbi Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine
    R W King
    Avid Therapeutics, Inc, Philadelphia, Pennsylvania 19104, USA
    Antimicrob Agents Chemother 42:3179-86. 1998
  2. ncbi Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication
    R B Perni
    Avid Therapeutics, Inc, Philadelphia, PA 19104, USA
    Bioorg Med Chem Lett 10:2687-90. 2000

Collaborators

Detail Information

Publications2

  1. ncbi Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine
    R W King
    Avid Therapeutics, Inc, Philadelphia, Pennsylvania 19104, USA
    Antimicrob Agents Chemother 42:3179-86. 1998
    ..Therefore, we concluded that the antiviral activity of AT-61 is specific for HBV replication and most likely occurs at one of the steps between the synthesis of viral RNA and the packaging of pregenomic RNA into immature core particles...
  2. ncbi Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication
    R B Perni
    Avid Therapeutics, Inc, Philadelphia, PA 19104, USA
    Bioorg Med Chem Lett 10:2687-90. 2000
    ..A series of substituted analogues of phenylpropenamide 6 has been prepared and evaluated in the HepAD38 cellular assay. Structure-activity relationships of this series are discussed...